PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction.

Area of Science:

• Neuroscience
• Cell Biology
• Genetics

Background:

• Coiled-coil-helix-coiled-coil-helix domain containing protein 2 (CHCHD2) mutations are linked to autosomal dominant Parkinson's disease (PD), Alzheimer's disease, and frontotemporal dementia.
• Understanding the molecular mechanisms underlying CHCHD2-associated neurodegeneration is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the role of CHCHD2 in mitochondrial function and its interaction with the mitochondrial contact site and cristae organizing system (MICOS) complex.
• To explore the potential of Elamipretide as a therapeutic intervention for CHCHD2 mutation-induced neurodegenerative defects.

Main Methods:

• Generated isogenic human embryonic stem cell (hESC) lines with PD-associated CHCHD2 mutations (R145Q, Q126X) using CRISPR-Cas9 technology.
• Utilized super-resolution microscopy to examine CHCHD2 localization and interaction with MICOS in hESCs and neural progenitor cells (NPCs).
• Assessed mitochondrial function, CHCHD2-CHCHD10 interaction, and the effect of Elamipretide on mutant NPCs.

Main Results:

• CHCHD2 localizes with MICOS in mitochondria, and CHCHD2 mutations impair mitochondrial function, reduce MICOS components, and lead to abnormal mitochondrial cristae.
• PD-associated CHCHD2 mutations disrupt the interaction with CHCHD10, and knockdown of either protein affects MICOS and mitochondrial cristae.
• Elamipretide treatment improved mitochondrial oxidative phosphorylation and attenuated mitochondrial dysfunction in NPCs with CHCHD2 R145Q mutation.

Conclusions:

• The CHCHD2-CHCHD10 complex is implicated in maintaining mitochondrial integrity and function, suggesting it as a potential therapeutic target for PD and related disorders.
• Elamipretide demonstrates therapeutic potential for mitigating mitochondrial dysfunction in CHCHD2 mutation-linked Parkinson's disease.